- Home
- BUDA vs CNTX Comparison
BUDA vs CNTX Comparison
Compare BUDA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUDA | CNTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 132.3M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BUDA | CNTX |
|---|---|---|
| Price | $9.10 | $2.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 42.1K | ★ 2.2M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $12,486,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.24 | ★ N/A |
| Revenue Growth | ★ 33.11 | N/A |
| 52 Week Low | $6.85 | $0.49 |
| 52 Week High | $12.00 | $2.85 |
Technical Indicators
Market Signals| Indicator | BUDA | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.77 |
| Support Level | N/A | $2.06 |
| Resistance Level | N/A | $2.85 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 57.53 |
Price Performance
Historical ComparisonAbout BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a competitive beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never pasteurized, never HPP- processed, never UV- treated and always cold.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.